Makers Laboratories Ltd. is a pharmaceutical company, which engages in manufacturing and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 121 full-time employees. The firm is engaged in the manufacturing and marketing of pharmaceuticals. The firm operates through the pharmaceuticals segment. Its product portfolio covers a range of general health therapeutic segments. Its formulation brands are Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range) and Exylin (Amoxycillin range). Its Inspira retail packs division includes acid regulatory (PPIS), anthelmintics, anti-allergic, anti-asthmatic, anti-biotics, anti-diabetics, anti-diarrheal, anti-emetics and anti-nauseants, anti-fungal, anti-hypertensives, and others. Its Experia bulk packs division includes amoxycillin 250 mg capsules, betamethasone 0.5 mg tablets, cetirizine HCL 10 mg tablets, chloramphenicol capsules 250 mg, chloroquine phosphate 250 mg tablets, chlorpheniramine maleate 4 mg tablets, ciprofloxacin hydrochloride 250 mg tablets, and others.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.